PF-04418948 is a selective prostaglandin E receptor 2 antagonist used in receptor biology, inflammation research, and pharmacology studies. In supplier catalogs and technical databases, it is commonly identified as PF-04418948, pf 04418948, CAS 1078166-57-0, and 1078166-57-0. This molecule is especially relevant in projects focused on EP2-mediated signaling, where a defined and well-characterized antagonist is needed for screening, pathway validation, and translational model work. Available supplier data list PF-04418948 molecular formula as C23H20FNO5 and molecular weight as 409.41, while PF-04418948 chemical structure is routinely used as a confirmation point during compound qualification and catalog comparison. The compound is also associated with the naming variant Pfizer PF-04418948 in published and commercial reference materials.
Application of PF-04418948
In research settings, inhibitor PF-04418948 is applied in studies of prostaglandin signaling, inflammation, airway biology, vascular responses, and receptor-selective pharmacology. Because EP2 is involved in cAMP-linked signaling and tissue-specific physiological responses, this compound is useful in experiments designed to separate EP2-driven effects from those mediated by other prostanoid receptors. It is also relevant for teams building receptor-focused assay panels and comparing selective antagonists across related targets. This makes PF-04418948 valuable not only for basic signaling work, but also for discovery-stage programs that require a reliable pharmacological tool with published in vitro and in vivo characterization.
In Vitro
In vitro, PF-04418948 is recognized as a strong and selective antagonist of the EP2 receptor, showing an IC50 of 16 nM against the human EP2 subtype. According to Tocris, it demonstrates more than 2000-fold selectivity versus EP1, EP3, EP4, DP1, and CRTH2 receptors, while also showing minimal off-target interaction across a wider panel of GPCRs and ion channels at 10 μM. The same source indicates that PF-04418948 suppresses PGE2-driven increases in intracellular cAMP, which supports its use in receptor signaling assays and cellular mechanism studies.
In Vivo
In vivo, PF-04418948 has also demonstrated oral efficacy and functional antagonistic activity in rat models. Published characterization data report that it attenuated agonist-induced cutaneous blood flow responses in rats, supporting its use as a practical in vivo probe for EP2 receptor function. This strengthens its relevance for translational work where researchers need continuity between receptor-level in vitro data and measurable physiological outcomes in animal studies.
Biochemical and Physiological Actions
Biochemically, PF-04418948 blocks EP2 receptor activation and reduces downstream cAMP signaling triggered by prostaglandin E2. Physiologically, this is important because EP2 contributes to smooth muscle relaxation, vascular responses, and inflammatory signaling in selected tissues. Tocris also reports that the compound reverses PGE2-invoked relaxation of mouse trachea with an IC50 of 2.7 nM, which gives this antagonist added value in airway and prostanoid biology research.
Features and Benefits of PF-04418948
- Defined identifiers including CAS 1078166-57-0, PF-04418948 molecular formula, and searchable PF-04418948 chemical structure
- Potent and selective EP2 antagonism suitable for receptor signaling, inflammation, and translational pharmacology studies
- Useful for researchers comparing Pfizer PF-04418948 with other prostanoid receptor modulators in validated workflows
For EBC-411051, PF-04418948 offers a strong balance of structural clarity, receptor selectivity, and experimentally documented activity that supports confident use in modern EP2-focused research.
Powered by Bioz